-transparent.png){kind=logo}
4-Demethoxydaunorubicin (4-DMDR) was administered orally at the dose of 15 mg/m2 daily for 3 consecutive days at three-weekly intervals to 28 patients with advanced pretreated breast cancer and 9 patients with disseminated pretreated melanoma. A partial remission was observed in 6 out of 20 evaluable breast cancer patients (30%) for a median duration of 6 months and in one out of 7 evaluable patients with melanoma (14%) for a duration of 3 months. Side-effects included leucopenia in 78% of patients (less than 1000 wbc/cmm in 8%), nausea in 32% and mild vomiting in 16%. The preliminary results of this ongoing study on 4-DMDR administered orally show that the regimen is well tolerated in the majority of patients and that it has antitumour activity in advanced breast cancer.
A Martoni, and
M A Pacciarini, and
F Pannuti
January 1988,
Acta oncologica (Stockholm, Sweden),
A Martoni, and
M A Pacciarini, and
F Pannuti
April 1987,
European journal of cancer & clinical oncology,
A Martoni, and
M A Pacciarini, and
F Pannuti
January 1988,
Cancer chemotherapy and pharmacology,
A Martoni, and
M A Pacciarini, and
F Pannuti
January 2004,
Acta oncologica (Stockholm, Sweden),
A Martoni, and
M A Pacciarini, and
F Pannuti
January 1987,
Cancer chemotherapy and pharmacology,
A Martoni, and
M A Pacciarini, and
F Pannuti
August 1986,
Onkologie,
A Martoni, and
M A Pacciarini, and
F Pannuti
February 1988,
Tumori,
A Martoni, and
M A Pacciarini, and
F Pannuti
April 2000,
Annals of oncology : official journal of the European Society for Medical Oncology,
A Martoni, and
M A Pacciarini, and
F Pannuti
June 1994,
American journal of clinical oncology,
A Martoni, and
M A Pacciarini, and
F Pannuti
January 1986,
Cancer chemotherapy and pharmacology,
